The rapid identification of genetic risk factors for common, complex diseases poses great opportunities and challenges for public health. Genetic information is increasingly being utilized as part of commercial efforts, including direct-to-consumer (DTC) genetic testing to provide risk information on common diseases to consumers. Very few empirical data have been gathered to understand the characteristics of DTC test consumers, the psychological, behavioral and health impact, and the ethical, legal and social issues associated with DTC services. In the proposed research, we will survey users of the two leading US companies providing DTC genetic testing (23andMe and Navigenics) regarding their response to genetic tests for common diseases of interest, including heart disease, diabetes, Alzheimer's disease, arthritis, and breast, colon, lung and prostate cancers. Each company now has thousands of customers and each anticipates extensive sales in coming years. Each has agreed to allow our group to survey consumers using third-party data collection and analysis procedures that will enable an independent consideration of the benefits and risks of DTC testing in this format. The companies have also agreed to provide genetic test information (with respondents'permission) for analyses. A total of 1000 consumers (500 from each company) will be surveyed via the Internet before receipt of genetic test results, and we will survey this sample again at 1-2 weeks and six months following receipt of results. To carry out the proposed research, we have assembled an interdisciplinary team of experts with backgrounds in medicine, genetic testing policy and practice, health communication, genetic counseling, health psychology, health law, bioethics and web survey design. Many team members have collaborated on prior, related ELSI-funded research.
Our aims are as follows: 1) to describe who seeks genetic testing and why, collecting information on demographics, motivations for seeking testing, and understanding of genetics;2) to describe the impact of DTC genetic testing, including psychological impact, risk perceptions and comprehension, and personal utility of services;and 3) to assess what consumers do with their genetic information in the domains of health behaviors, insurance changes, information seeking, and communication with family and health care providers. This study will produce results that can be translated into recommendations to guide practice and policy in this rapidly emerging area.
Genetic information is increasingly being utilized as part of commercial efforts, including direct-to-consumer (DTC) genetic testing to provide risk information on common diseases to consumers. We will survey customers of the two leading DTC genetic test services in the U.S., using independent third party data collection and analysis to provide data on who is ordering these tests and why, and what its benefits and risks may be. This study will produce results that can be translated into recommendations to guide practice and policy in this rapidly emerging area.
|Baptista, Natalie M; Christensen, Kurt D; Carere, Deanna Alexis et al. (2016) Adopting genetics: motivations and outcomes of personal genomic testing in adult adoptees. Genet Med 18:924-32|
|Lebo, Matthew S; Sutti, Sheila; Green, Robert C (2016) ""Big Data"" Gets Personal. Sci Transl Med 8:322fs3-3fs3|
|Wang, Catharine; Gordon, Erynn S; Norkunas, Tricia et al. (2016) A randomized trial Examining The Impact Of Communicating Genetic And Lifestyle Risks For Obesity. Obesity (Silver Spring) 24:2481-2490|
|Carere, Deanna Alexis; Kraft, Peter; Kaphingst, Kimberly A et al. (2016) Consumers report lower confidence in their genetics knowledge following direct-to-consumer personal genomic testing. Genet Med 18:65-72|
|Delaney, Susan K; Hultner, Michael L; Jacob, Howard J et al. (2016) Toward clinical genomics in everyday medicine: perspectives and recommendations. Expert Rev Mol Diagn 16:521-32|
|Krier, Joel; Barfield, Richard; Green, Robert C et al. (2016) Reclassification of genetic-based risk predictions as GWAS data accumulate. Genome Med 8:20|
|Waisbren, Susan E; BÃ¤ck, Danielle K; Liu, Christina et al. (2015) Parents are interested in newborn genomic testing during the early postpartum period. Genet Med 17:501-4|
|Vassy, Jason L; Korf, Bruce R; Green, Robert C (2015) How to know when physicians are ready for genomic medicine. Sci Transl Med 7:287fs19|
|Krier, Joel B; Green, Robert C (2015) Management of Incidental Findings in Clinical Genomic Sequencing. Curr Protoc Hum Genet 87:9.23.1-16|
|Green, Robert C; Christensen, Kurt D; Cupples, L Adrienne et al. (2015) A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease. Alzheimers Dement 11:1222-30|
Showing the most recent 10 out of 58 publications